PortalPublikationenMeasurable residual disease (MRD) status before allogeneic h...

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Standard

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). / Maffini, Enrico; Labopin, Myriam; Beelen, Dietrich Wilhelm; Kroeger, Nicolaus; Arat, Mutlu; Wilson, Keith M O; Bay, Jacques-Olivier; Ganser, Arnold; Martin, Hans; Passweg, Jakob; Kottaridis, Panagiotis D; Yakoub-Agha, Ibrahim; Porras, Rocio Parody; Wagner, Eva Maria; Esteve, Jordi; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad.

in: BONE MARROW TRANSPL, Jahrgang 57, Nr. 10, 10.2022, S. 1556-1563.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Maffini, E, Labopin, M, Beelen, DW, Kroeger, N, Arat, M, Wilson, KMO, Bay, J-O, Ganser, A, Martin, H, Passweg, J, Kottaridis, PD, Yakoub-Agha, I, Porras, RP, Wagner, EM, Esteve, J, Lanza, F, Nagler, A & Mohty, M 2022, 'Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)', BONE MARROW TRANSPL, Jg. 57, Nr. 10, S. 1556-1563. https://doi.org/10.1038/s41409-022-01748-w

APA

Maffini, E., Labopin, M., Beelen, D. W., Kroeger, N., Arat, M., Wilson, K. M. O., Bay, J-O., Ganser, A., Martin, H., Passweg, J., Kottaridis, P. D., Yakoub-Agha, I., Porras, R. P., Wagner, E. M., Esteve, J., Lanza, F., Nagler, A., & Mohty, M. (2022). Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPL, 57(10), 1556-1563. https://doi.org/10.1038/s41409-022-01748-w

Vancouver

Maffini E, Labopin M, Beelen DW, Kroeger N, Arat M, Wilson KMO et al. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPL. 2022 Okt;57(10):1556-1563. https://doi.org/10.1038/s41409-022-01748-w

Bibtex

@article{c9870f68cbe249ac96fdc8c43781f8d2,
title = "Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)",
abstract = "Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.",
keywords = "Acute Disease, Adult, Bone Marrow, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute/therapy, Neoplasm, Residual, Neoplasms, Second Primary, Recurrence, Retrospective Studies, Transplantation Conditioning",
author = "Enrico Maffini and Myriam Labopin and Beelen, {Dietrich Wilhelm} and Nicolaus Kroeger and Mutlu Arat and Wilson, {Keith M O} and Jacques-Olivier Bay and Arnold Ganser and Hans Martin and Jakob Passweg and Kottaridis, {Panagiotis D} and Ibrahim Yakoub-Agha and Porras, {Rocio Parody} and Wagner, {Eva Maria} and Jordi Esteve and Francesco Lanza and Arnon Nagler and Mohamad Mohty",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = oct,
doi = "10.1038/s41409-022-01748-w",
language = "English",
volume = "57",
pages = "1556--1563",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

AU - Maffini, Enrico

AU - Labopin, Myriam

AU - Beelen, Dietrich Wilhelm

AU - Kroeger, Nicolaus

AU - Arat, Mutlu

AU - Wilson, Keith M O

AU - Bay, Jacques-Olivier

AU - Ganser, Arnold

AU - Martin, Hans

AU - Passweg, Jakob

AU - Kottaridis, Panagiotis D

AU - Yakoub-Agha, Ibrahim

AU - Porras, Rocio Parody

AU - Wagner, Eva Maria

AU - Esteve, Jordi

AU - Lanza, Francesco

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/10

Y1 - 2022/10

N2 - Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.

AB - Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.

KW - Acute Disease

KW - Adult

KW - Bone Marrow

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute/therapy

KW - Neoplasm, Residual

KW - Neoplasms, Second Primary

KW - Recurrence

KW - Retrospective Studies

KW - Transplantation Conditioning

U2 - 10.1038/s41409-022-01748-w

DO - 10.1038/s41409-022-01748-w

M3 - SCORING: Journal article

C2 - 35835997

VL - 57

SP - 1556

EP - 1563

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 10

ER -